Patients & familles
Professionnels
Hôpital
TitreAuteur(s)RevueAnnéeVol­umePagePMID
Sequenc­ing of Tax­anes and New Andro­gen-tar­get­ed Ther­a­pies in Metasta­t­ic Cas­tra­tion-resis­tant Prostate Can­cer: Results of the Inter­na­tion­al Mul­ti­cen­tre Ret­ro­spec­tive CATS Database.Delanoy, N ; Hardy-Bessard, AC ; Efs­tathiou, E ; Le Moulec, S ; Bas­so, U ; Bir­tle, A & alEur Urol Oncol20181467–47531158090
[Nau­sea and vom­it­ing induced by chemotherapy].Scot­té, F ; Chas­tenet, M ; Leroy, P ; Aumont, L ; Goudi­a­by, C ; Leg­eay, K & alRev Prat20196949–5430983284
[Sup­port­ive care in oncol­o­gy: def­i­n­i­tion, orga­ni­za­tion, limits].Scot­té, F ; Chas­tenet, M ; Leroy, P ; Aumont, L ; Goudi­a­by, C ; Leg­eay, K & alRev Prat20196933–3830983282
[Pri­ma­ry pro­phy­lax­is of venous throm­boem­bolism in ambu­la­to­ry can­cer patients treat­ed with anti­neo­plas­tic agents].Debour­deau, P ; Simonin, C ; Car­basse, C ; Debour­deau, T ; Zam­mit, C ; Scot­té, FRev Med Interne201930928244
Side effects of immunother­a­py: a con­stant chal­lenge for oncologists.Scot­té, F ; Rat­ta, R ; Beuze­boc, PCurr Opin Oncol201931280–28530925538
[Anti­neo­plas­tic drug induced nau­sea and vom­it­ing: What is the clin­i­cal prac­tice in 2018? An update of AFSOS clin­i­cal guidelines].Jovenin, N ; Eche-Gass, A ; Chèze, S ; Lau­nay-Vach­er, V ; Mayeur, D ; Rey, JB & alBull Can­cer2019106497–50930922554
Effect of Adding Doc­etax­el to Andro­gen-Depri­va­tion Ther­a­py in Patients With High-Risk Prostate Can­cer With Ris­ing Prostate-Spe­cif­ic Anti­gen Lev­els After Pri­ma­ry Local Ther­a­py: A Ran­dom­ized Clin­i­cal Trial.Oudard, S ; Latorz­eff, I ; Caty, A ; Miglian­i­co, L ; Sevin, E ; Hardy-Bessard, AC & alJAMA Oncol20195623–63230703190
Treat­ment and Pre­ven­tion of Can­cer-Asso­ci­at­ed Throm­bo­sis in Frail Patients: Tai­lored Management.Scot­té, F ; Leroy, P ; Chas­tenet, M ; Aumont, L ; Benatar, V ; Elalamy, ICan­cers (Basel)20191130621020
Spinal cord stim­u­la­tion for chron­ic refrac­to­ry pain: Long-term effec­tive­ness and safe­ty data from a mul­ti­cen­tre registry.Brinzeu, A ; Cuny, E ; Fontaine, D ; Mertens, P ; Luyet, PP ; Van den Abeele, C & alEur J Pain2019231031–104430597719
Patient-report­ed out­comes (PROs) as a rou­tine mea­sure for can­cer inpa­tients: the final miss­ing piece of the puzzle?Brandt, J ; Scot­té, F ; Jor­dan, KAnn Oncol201930167–16930481270
[French ccA­FU guide­lines — Update 2018–2020: Prostate cancer].Rozet, F ; Hen­nequin, C ; Beau­val, JB ; Beuze­boc, P ; Cormi­er, L ; Fromont-Han­kard, G & alProg Urol201828S79-S13030392712
Devel­op­ment of a Pre­dic­tion Tool for Exclu­sive Locore­gion­al Recur­rence After Rad­i­cal Cys­tec­to­my in Patients With Mus­cle-Inva­sive Blad­der Cancer.Nec­chi, A ; Pond, GR ; Mos­chi­ni, M ; Pli­mack, ER ; Niegisch, G ; Yu, EY & alClin Gen­i­tourin Cancer2019177–14.e330292628
French rec­om­men­da­tions for osteo­poro­sis pre­ven­tion and treat­ment in patients with prostate can­cer treat­ed by andro­gen deprivation.Briot, K ; Pac­cou, J ; Beuze­boc, P ; Bon­neterre, J ; Bou­vard, B ; Con­favreux, CB & alJoint Bone Spine20198621–2830287350
[Impact of beau­ty and well-being care assessed in a nation­al sur­vey includ­ing 1166 individuals].Saghatchi­an, M ; Bouleuc, C ; Naudet, C ; Arnaud, S ; Papaz­ian, P ; Scot­té, F & alBull Can­cer2018105671–67830099993
A quick scop­ing review of effi­ca­cy, safe­ty, eco­nom­ic, and health-relat­ed qual­i­ty-of-life out­comes of short- and long-act­ing ery­thro­poiesis-stim­u­lat­ing agents in the treat­ment of chemother­a­py-induced ane­mia and chron­ic kid­ney dis­ease anemia.Arantes, LH ; Craw­ford, J ; Gas­con, P ; Latymer, M ; Lau­nay-Vach­er, V ; Rol­land, C & alCrit Rev Oncol Hematol201812979–9030097240
Suni­tinib Pri­or to Planned Nephrec­to­my in Metasta­t­ic Renal Cell Car­ci­no­ma: Angio­gen­e­sis Bio­mark­ers Pre­dict Clin­i­cal Out­come in the Prospec­tive Phase II PREINSUT Trial.Mauge, L ; Mejean, A ; Fournier, L ; Pereira, H ; Eti­enne-Grimal­di, MC ; Levion­nois, E & alClin Can­cer Res2018245534–554230061359
Diag­no­sis, assess­ment and man­age­ment of con­sti­pa­tion in advanced can­cer: ESMO Clin­i­cal Prac­tice Guidelines.Larkin, PJ ; Cherny, NI ; La Carpia, D ; Gugliel­mo, M ; Ost­gathe, C ; Scot­té, F & alAnn Oncol201829iv111-iv12530016389
Impact of the Num­ber of Cycles of Plat­inum Based First Line Chemother­a­py for Advanced Urothe­lial Carcinoma.Son­pavde, GP ; Mar­i­ani, L ; Lo Vul­lo, S ; Rag­gi, D ; Gian­natem­po, P ; Bamias, A & alJ Urol20182001207–121430012366
Address­ing the qual­i­ty of life needs of old­er patients with can­cer: a SIOG con­sen­sus paper and prac­ti­cal guide.Scot­té, F ; Bossi, P ; Car­o­la, E ; Cud­en­nec, T ; Die­lenseger, P ; Gomes, F & alAnn Oncol2018291718–172630010772
Peri­toneal tuber­cu­lo­sis asso­ci­at­ed with adreno­cor­ti­col prim­i­tive neo­plasm mim­ic­k­ing a peri­toneal car­ci­nosis: a case report.Lamuraglia, M ; Bar­ras­cout, E ; Medioni, JEur J Gynaecol Oncol201637543–54529894081
Elder­ly patients with metasta­t­ic renal cell car­ci­no­ma: posi­tion paper from the Inter­na­tion­al Soci­ety of Geri­atric Oncology.Kanes­varan, R ; Le Saux, O ; Motzer, R ; Choueiri, TK ; Scot­té, F ; Bell­munt, J & alLancet Oncol201819e317-e32629893263
Stereo­tac­tic radi­a­tion ther­a­py in the strat­e­gy of treat­ment of metasta­t­ic renal cell car­ci­no­ma: A study of the Getug group.Mey­er, E ; Pasquier, D ; Bernadou, G ; Calais, G ; Maroun, P ; Bossi, A & alEur J Cancer20189838–4729864737
Suni­tinib Alone or after Nephrec­to­my in Metasta­t­ic Renal-Cell Carcinoma.Méjean, A ; Ravaud, A ; Thezenas, S ; Colas, S ; Beau­val, JB ; Ben­salah, K & alN Engl J Med2018379417–42729860937
Over­weight is asso­ci­at­ed to a bet­ter prog­no­sis in metasta­t­ic col­orec­tal can­cer: A pooled analy­sis of FFCD trials.Apari­cio, T ; Ducreux, M ; Faroux, R ; Bar­bi­er, E ; Man­fre­di, S ; Lecomte, T & alEur J Cancer2018981–929807237
Effi­ca­cy of cabaz­i­tax­el rechal­lenge in heav­i­ly treat­ed patients with metasta­t­ic cas­tra­tion-resis­tant prostate cancer.Thibault, C ; Eymard, JC ; Bir­tle, A ; Krain­er, M ; Bacia­rel­lo, G ; Flé­chon, A & alEur J Cancer20189741–4829636272
Opti­mal cut-off for neu­trophil-to-lym­pho­cyte ratio: Fact or Fan­ta­sy? A prospec­tive cohort study in metasta­t­ic can­cer patients.Vano, YA ; Oudard, S ; By, MA ; Têtu, P ; Thibault, C ; Aboudag­ga, H & alPLoS One201813e019504229624591
Three Ver­sus 6 Months of Oxali­platin-Based Adju­vant Chemother­a­py for Patients With Stage III Colon Can­cer: Dis­ease-Free Sur­vival Results From a Ran­dom­ized, Open-Label, Inter­na­tion­al Dura­tion Eval­u­a­tion of Adju­vant (IDEA) France, Phase III Trial.André, T ; Vernerey, D ; Mineur, L ; Ben­nouna, J ; Desrame, J ; Faroux, R & alJ Clin Oncol2018361469–147729620995
Immunother­a­py in head and neck can­cers: A new chal­lenge for immu­nol­o­gists, pathol­o­gists and clinicians.Outh-Gauer, S ; Alt, M ; Le Tourneau, C ; Augustin, J ; Broudin, C ; Gasne, C & alCan­cer Treat Rev20186554–6429547766
Apa­lu­tamide Treat­ment and Metas­ta­sis-free Sur­vival in Prostate Cancer.Smith, MR ; Saad, F ; Chowd­hury, S ; Oudard, S ; Hadaschik, BA ; Graff, JN & alN Engl J Med20183781408–141829420164
Physi­cians” deci­sion about long-term throm­bo­pro­phy­lax­is in can­cer out­pa­tients: CAT AXIS, a case vignette study on clin­i­cal prac­tice in France.Scot­té, F ; Elalamy, I ; Mayeur, D ; Mey­er, GSup­port Care Cancer2018262049–205629353416
Ate­zolizum­ab in Plat­inum-treat­ed Local­ly Advanced or Metasta­t­ic Urothe­lial Car­ci­no­ma: Out­comes by Pri­or Num­ber of Regimens.Perez-Gra­cia, JL ; Lori­ot, Y ; Rosen­berg, JE ; Powles, T ; Nec­chi, A ; Hus­sain, SA & alEur Urol201729273410
Trastuzum­ab beyond pro­gres­sion in patients with HER2-pos­i­tive advanced gas­tric ade­no­car­ci­no­ma: a mul­ti­cen­ter AGEO study.Palle, J ; Tougeron, D ; Pozet, A ; Soularue, E ; Artru, P ; Leroy, F & alOnco­tar­get20178101383–10139329254172
Euro­pean Soci­ety for Med­ical Oncol­o­gy (ESMO) posi­tion paper on sup­port­ive and pal­lia­tive care.Jor­dan, K ; Aapro, M ; Kaasa, S ; Ripa­mon­ti, CI ; Scot­té, F ; Strass­er, F & alAnn Oncol20182936–4329253069
High Risk of Anal and Rec­tal Can­cer in Patients With Anal and/or Peri­anal Crohn”s Disease.Beaugerie, L ; Car­rat, F ; Nahon, S ; Zeitoun, JD ; Sabaté, JM ; Peyrin-Biroulet, L & alClin Gas­troen­terol Hepatol201816892–899.e229199142
Pat­terns of relapse in poor-prog­no­sis germ-cell tumours in the GETUG 13 tri­al: Impli­ca­tions for assess­ment of brain metastases.Lori­ot, Y ; Pagliaro, L ; Flé­chon, A ; Mar­diak, J ; Geof­frois, L ; Ker­brat, P & alEur J Cancer201787140–14629149760
Anti­cancer Activ­i­ty and Tol­er­ance of Treat­ments Received Beyond Pro­gres­sion in Men Treat­ed Upfront with Andro­gen Depri­va­tion Ther­a­py With or With­out Doc­etax­el for Metasta­t­ic Cas­tra­tion-naïve Prostate Can­cer in the GETUG-AFU 15 Phase 3 Trial.Lavaud, P ; Gravis, G ; Foulon, S ; Joly, F ; Oudard, S ; Pri­ou, F & alEur Urol201873696–70329074061
A Prac­ti­cal Approach to Fatigue Man­age­ment in Col­orec­tal Cancer.Aapro, M ; Scotte, F ; Bouil­let, T ; Cur­row, D ; Vigano, AClin Col­orec­tal Cancer201716275–28529066018
Pre­ven­tion and treat­ment of can­cer-asso­ci­at­ed throm­bo­sis in France: A nation­al sur­vey among vas­cu­lar dis­ease and sup­port­ive care specialists.Mahé, I ; Scot­té, F ; Rey, JB ; Elalamy, I ; Lam­blin, A ; Mayeur, D & alJ Med Vasc201742255–26228964384
Radi­um 223 dichlo­ride for prostate can­cer treatment.Deshayes, E ; Roumigu­ie, M ; Thibault, C ; Beuze­boc, P ; Cachin, F ; Hen­nequin, C & alDrug Des Dev­el Ther2017112643–265128919714
Lack of Effec­tive­ness of Postchemother­a­py Lym­phadenec­to­my in Blad­der Can­cer Patients with Clin­i­cal Evi­dence of Metasta­t­ic Pelvic or Retroperi­toneal Lymph Nodes Only: A Propen­si­ty Score-based Analysis.Nec­chi, A ; Mar­i­ani, L ; Lo Vul­lo, S ; Yu, EY ; Woods, ME ; Wong, YN & alEur Urol Focus20195242–24928753897
Robot-assist­ed Ver­sus Open Rad­i­cal Cys­tec­to­my in Patients Receiv­ing Peri­op­er­a­tive Chemother­a­py for Mus­cle-inva­sive Blad­der Can­cer: The Oncologist”s Per­spec­tive from a Mul­ti­cen­tre Study.Nec­chi, A ; Pond, GR ; Smal­done, MC ; Pal, SK ; Chan, K ; Wong, YN & alEur Urol Focus20184937–94528753879
Prog­nos­tic Bio­mark­ers Used for Localised Prostate Can­cer Man­age­ment: A Sys­tem­at­ic Review.Lamy, PJ ; Allo­ry, Y ; Gauchez, AS ; Asse­lain, B ; Beuze­boc, P ; de Cre­moux, P & alEur Urol Focus20184790–80328753865
Long-Term Results of a High­ly Per­form­ing Con­for­mal Elec­tron Ther­a­py Tech­nique for Chest Wall Irra­di­a­tion After Mastectomy.Grel­li­er Aded­jouma, N ; Chevri­er, M ; Four­quet, A ; Cos­ta, E ; Xu, H ; Berg­er, F & alInt J Radi­at Oncol Biol Phys201798206–21428586961
Abi­raterone plus Pred­nisone in Metasta­t­ic, Cas­tra­tion-Sen­si­tive Prostate Cancer.Fizazi, K ; Tran, N ; Fein, L ; Mat­sub­ara, N ; Rodriguez-Antolin, A ; Alek­seev, BY & alN Engl J Med2017377352–36028578607
Per­cu­ta­neous radiofre­quen­cy abla­tion of lung metas­tases from col­orec­tal car­ci­no­ma under C‑arm cone beam CT guidance.Amouyal, G ; Per­not, S ; Déan, C ; Chol­ley, B ; Scot­té, F ; Sapo­val, M & alDiagn Interv Imaging201798793–79928571704
Iden­ti­fy­ing pre­dic­tive fac­tors of chemother­a­py-induced nau­sea and vom­it­ing (CINV): a nov­el approach.Scot­té, FAnn Oncol2017281165–116728398565
Part­ner­ing with patients in trans­la­tion­al oncol­o­gy research: eth­i­cal approach.Mamz­er, MF ; Duchange, N ; Dar­quy, S ; Mar­vanne, P ; Ram­baud, C ; Mar­si­co, G & alJ Transl Med2017157428390420
First-line Beva­cizum­ab and Pacli­tax­el for HER2-neg­a­tive Metasta­t­ic Breast Can­cer: A French Ret­ro­spec­tive Obser­va­tion­al Study.Dieras, V ; Pop, S ; Berg­er, F ; Dujar­ic, ME ; Beuze­boc, P ; Escalup, L & alAnti­cancer Res2017371403–140728314310
Rela­tion­ship between mag­net­ic res­o­nance imag­ing char­ac­ter­is­tics and plas­mat­ic lev­els of MMP2 and MMP9 in patients with recur­rent high-grade gliomas treat­ed by Beva­cizum­ab and Irinotecan.Fari­na, P ; Tabouret, E ; Lehmann, P ; Bar­rie, M ; Petrire­na, G ; Campel­lo, C & alJ Neu­roon­col2017132433–43728265824
Tar­get­ed Ther­a­pies in HER2-Over­ex­press­ing Metasta­t­ic Breast Cancer.Labi­di, S ; Mejri, N ; Lagha, A ; Daoud, N ; El Ben­na, H ; Afrit, M & alBreast Care (Basel)201611418–42228228709
Sup­port­ive Care Orga­ni­za­tion in France: a nation­al in-depth sur­vey among patients and oncologists.Scot­té, F ; Hervé, C ; Leroy, P ; Tourani, JM ; Ben­sadoun, RJ ; Bugat, ME & alSup­port Care Cancer2017252111–211828220314
[Cur­rent events in immunother­a­py for upper aerodi­ges­tive tract cancer].Outh-Gauer, S ; Le Tourneau, C ; Broudin, C ; Scotte, F ; Rous­sel, H ; Hans, S & alAnn Pathol20173779–8928111039
Basi cer­vi­cal inflam­ma­to­ry mass.Benkhatar, H ; Scotte, F ; Lac­cour­r­eye, O ; Benoit, CEur Ann Otorhi­no­laryn­gol Head Neck Dis2017134365–36728017542
The effects of aminos­al­i­cy­lates or thiop­urines on the risk of col­orec­tal can­cer in inflam­ma­to­ry bow­el disease.Car­rat, F ; Sek­sik, P ; Colombel, JF ; Peyrin-Biroulet, L ; Beaugerie, LAli­ment Phar­ma­col Ther201745533–54127995656
Pre­lim­i­nary expe­ri­ence of the con­cur­rent use of radio­surgery and T‑DM1 for brain metas­tases in HER2-pos­i­tive metasta­t­ic breast cancer.Ger­aud, A ; Xu, HP ; Beuze­boc, P ; Kiro­va, YMJ Neu­roon­col201713169–7227995546
Use of iron sucrose and red blood cell trans­fu­sions in anaemic can­cer patients in France (OncoFer study).Lupor­si, E ; Toledano, A ; Spaeth, D ; Scot­té, F ; Espié, M ; Per­ot, S & alSup­port Care Cancer201725973–98227915456
Nomo­gram-based Pre­dic­tion of Over­all Sur­vival in Patients with Metasta­t­ic Urothe­lial Car­ci­no­ma Receiv­ing First-line Plat­inum-based Chemother­a­py: Ret­ro­spec­tive Inter­na­tion­al Study of Invasive/Advanced Can­cer of the Urothe­li­um (RISC).Nec­chi, A ; Son­pavde, G ; Lo Vul­lo, S ; Gia­rdiel­lo, D ; Bamias, A ; Crabb, SJ & alEur Urol201771281–28927726966
Chemother­a­py in hor­mone-sen­si­tive metasta­t­ic prostate can­cer: Evi­dences and uncer­tain­ties from the literature.Gravis, G ; Audenet, F ; Irani, J ; Tim­sit, MO ; Barthele­my, P ; Beuze­boc, P & alCan­cer Treat Rev201755211–21727665366
Epi­cure: a Euro­pean epi­demi­o­log­i­cal study of patients with an advanced or metasta­t­ic Urothe­lial Car­ci­no­ma (UC) hav­ing pro­gressed to a plat­inum-based chemotherapy.Houédé, N ; Lock­er, G ; Lucas, C ; Par­ra, HS ; Bas­so, U ; Spaeth, D & alBMC Can­cer20161675227664126
Adju­vant Chemother­a­py After Rad­i­cal Cys­tec­to­my for Urothe­lial Blad­der Can­cer: Out­come and Prog­nos­tic Fac­tors for Sur­vival in a French Mul­ti­cen­ter, Con­tem­po­rary Cohort.Poues­sel, D ; Bas­tu­ji-Garin, S ; Houédé, N ; Vor­dos, D ; Lori­ot, Y ; Chevreau, C & alClin Gen­i­tourin Cancer201715e45-e5227554584
Cop­ing with a new­ly diag­nosed high-grade glioma: patient-care­giv­er dyad effects on qual­i­ty of life.Baum­star­ck, K ; Leroy, T ; Hami­dou, Z ; Tabouret, E ; Fari­na, P ; Bar­rié, M & alJ Neu­roon­col2016129155–6427300523
Effi­ca­cy and safe­ty of Vin­flu­nine for advanced or metasta­t­ic urothe­lial car­ci­no­ma in rou­tine prac­tice based on the French mul­ti-cen­tre CURVE study.Médioni, J ; Di Pal­ma, M ; Guil­lot, A ; Spaeth, D ; Théodore, CBMC Can­cer20161621726975779
Glioblas­toma in Tunisia: A ret­ro­spec­tive study about 41 cases.Ben Nasr, S ; Had­daoui, A ; Bach Ham­ba, S ; Lagha, A ; Labi­di, S ; Afrit, M & alTunis Med201593598–60126895120
Angiopoietin‑2 May Be Involved in the Resis­tance to Beva­cizum­ab in Recur­rent Glioblastoma.Labus­sière, M ; Che­neau, C ; Prahst, C ; Gál­lego Pérez-Lar­raya, J ; Fari­na, P ; Lom­bar­di, G & alCan­cer Invest20163439–4426735326
Andro­gen Depri­va­tion Ther­a­py (ADT) Plus Doc­etax­el Ver­sus ADT Alone in Metasta­t­ic Non cas­trate Prostate Can­cer: Impact of Metasta­t­ic Bur­den and Long-term Sur­vival Analy­sis of the Ran­dom­ized Phase 3 GETUG-AFU15 Trial.Gravis, G ; Boher, JM ; Joly, F ; Soulié, M ; Albiges, L ; Pri­ou, F & alEur Urol201670256–6226610858
Out­come Accord­ing to Elec­tive Pelvic Radi­a­tion Ther­a­py in Patients With High-Risk Local­ized Prostate Can­cer: A Sec­ondary Analy­sis of the GETUG 12 Phase 3 Ran­dom­ized Trial.Blan­chard, P ; Faivre, L ; Lesaunier, F ; Salem, N ; Mes­gouez-Nebout, N ; Deni­au-Alexan­dre, E & alInt J Radi­at Oncol Biol Phys20169485–9226576711
Excess risk of uri­nary tract can­cers in patients receiv­ing thiop­urines for inflam­ma­to­ry bow­el dis­ease: a prospec­tive obser­va­tion­al cohort study.Bour­ri­er, A ; Car­rat, F ; Colombel, JF ; Bou­vi­er, AM ; Abit­bol, V ; Marteau, P & alAli­ment Phar­ma­col Ther201643252–6126549003
RANK/OPG ratio of expres­sion in pri­ma­ry clear-cell renal cell car­ci­no­ma is asso­ci­at­ed with bone metas­ta­sis and prog­no­sis in patients treat­ed with anti-VEGFR-TKIs.Beuselinck, B ; Jean-Bap­tiste, J ; Couchy, G ; Job, S ; De Reynies, A ; Wolter, P & alBr J Cancer20151131313–2226528707
Ran­dom­ized phase III tri­al in elder­ly patients com­par­ing LV5FU2 with or with­out irinote­can for first-line treat­ment of metasta­t­ic col­orec­tal can­cer (FFCD 2001-02).Apari­cio, T ; Lavau-Denes, S ; Phe­lip, JM ; Mail­lard, E ; Jou­ve, JL ; Gar­got, D & alAnn Oncol201627121–726487578
Beva­cizum­ab with or with­out erlotinib as main­te­nance ther­a­py in patients with metasta­t­ic col­orec­tal can­cer (GERCOR DREAM; OPTIMOX3): a ran­domised, open-label, phase 3 trial.Tourni­gand, C ; Chibaudel, B ; Sam­son, B ; Schei­thauer, W ; Vernerey, D ; Mésange, P & alLancet Oncol2015161493–150526474518
Allel­ic loss of 9p21.3 is a prog­nos­tic fac­tor in 1p/19q codelet­ed anaplas­tic gliomas.Alen­torn, A ; Dehais, C ; Ducray, F ; Car­pen­tier, C ; Mokhtari, K ; Figarel­la-Branger, D & alNeu­rol­o­gy2015851325–3126385879
Andro­gen depri­va­tion ther­a­py plus doc­etax­el and estra­mus­tine ver­sus andro­gen depri­va­tion ther­a­py alone for high-risk localised prostate can­cer (GETUG 12): a phase 3 ran­domised con­trolled trial.Fizazi, K ; Faivre, L ; Lesaunier, F ; Del­va, R ; Gravis, G ; Rol­land, F & alLancet Oncol201516787–9426028518
Com­par­a­tive effec­tive­ness of gem­c­itabine plus cis­platin ver­sus methotrex­ate, vin­blas­tine, dox­oru­bicin, plus cis­platin as neoad­ju­vant ther­a­py for mus­cle-inva­sive blad­der cancer.Gal­sky, MD ; Pal, SK ; Chowd­hury, S ; Harsh­man, LC ; Crabb, SJ ; Wong, YN & alCan­cer20151212586–9325872978
First-line treat­ment with suni­tinib for type 1 and type 2 local­ly advanced or metasta­t­ic pap­il­lary renal cell car­ci­no­ma: a phase II study (SUPAP) by the French Gen­i­touri­nary Group (GETUG)†.Ravaud, A ; Oudard, S ; De Fromont, M ; Chevreau, C ; Gravis, G ; Zanet­ta, S & alAnn Oncol2015261123–825802238
Inter­me­di­ate analy­sis of a phase II tri­al assess­ing gem­c­itabine and cis­platin in locore­gion­al or metasta­t­ic penile squa­mous cell carcinoma.Houédé, N ; Dupuy, L ; Flé­chon, A ; Beuze­boc, P ; Gravis, G ; Laguerre, B & alBJU Int2016117444–925601543
The Euro­BioBank Net­work: 10 years of hands-on expe­ri­ence of col­lab­o­ra­tive, transna­tion­al biobank­ing for rare diseases.Mora, M ; Angeli­ni, C ; Big­na­mi, F ; Bod­in, AM ; Cri­mi, M ; Di Dona­to, JH & alEur J Hum Genet2015231116–2325537360
Imme­di­ate ver­sus deferred chemother­a­py after rad­i­cal cys­tec­to­my in patients with pT3-pT4 or N+ M0 urothe­lial car­ci­no­ma of the blad­der (EORTC 30994): an inter­group, open-label, ran­domised phase 3 trial.Stern­berg, CN ; Skonecz­na, I ; Kerst, JM ; Albers, P ; Fos­sa, SD ; Ager­baek, M & alLancet Oncol20151676–8625498218
Mul­ti­cen­tre ran­domised phase II tri­al of gemcitabine+platinum, with or with­out trastuzum­ab, in advanced or metasta­t­ic urothe­lial car­ci­no­ma over­ex­press­ing Her2.Oudard, S ; Culine, S ; Vano, Y ; Gold­wass­er, F ; Théodore, C ; Nguyen, T & alEur J Cancer20155145–5425459391
Effi­ca­cy and Safe­ty of Sequen­tial Use of Everolimus in Patients With Metasta­t­ic Renal Cell Car­ci­no­ma Pre­vi­ous­ly Treat­ed With Beva­cizum­ab With or With­out Inter­fer­on Ther­a­py: Results From the Euro­pean AVATOR Study.Thiery-Vuillemin, A ; Theodore, C ; Jacobasch, L ; Schmitz, J ; Papan­dreou, C ; Guil­lot, A & alClin Gen­i­tourin Cancer201513231–825456838
Prog­nos­tic Rel­e­vance of His­to­mol­e­c­u­lar Clas­si­fi­ca­tion of Dif­fuse Adult High-Grade Gliomas with Necrosis.Figarel­la-Branger, D ; Mokhtari, K ; Col­in, C ; Uro-Coste, E ; Jou­vet, A ; Dehais, C & alBrain Pathol201525418–2825407774
FOLFOX4 ver­sus sequen­tial dose-dense FOLFOX7 fol­lowed by FOLFIRI in patients with resectable metasta­t­ic col­orec­tal can­cer (MIROX): a prag­mat­ic approach to chemother­a­py tim­ing with peri­op­er­a­tive or post­op­er­a­tive chemother­a­py from an open-label, ran­dom­ized phase III trial.Heb­bar, M ; Chibaudel, B ; André, T ; Mineur, L ; Smith, D ; Lou­vet, C & alAnn Oncol201526340–725403578
Prog­nos­tic Fac­tors for Sur­vival in Non­cas­trate Metasta­t­ic Prostate Can­cer: Val­i­da­tion of the Glass Mod­el and Devel­op­ment of a Nov­el Sim­pli­fied Prog­nos­tic Model.Gravis, G ; Boher, JM ; Fizazi, K ; Joly, F ; Pri­ou, F ; Mari­no, P & alEur Urol201568196–20425277272
Twitter Facebook-square Youtube Linkedin-in Instagram

navigation

actualités